Histopathological‐Molecular Genetic Correlations in Referral Pathologist‐Diagnosed Low‐Grade “Oligodendroglioma”

@article{Sasaki2002HistopathologicalMolecularGC,
  title={Histopathological‐Molecular Genetic Correlations in Referral Pathologist‐Diagnosed Low‐Grade “Oligodendroglioma”},
  author={Hikaru Sasaki and Magdalena C. Zlatescu and Rebecca A. Betensky and Loki Johnk and Andrea N. Cutone and J. Gregory Cairncross and David N Louis},
  journal={JNEN: Journal of Neuropathology \& Experimental Neurology},
  year={2002},
  volume={61},
  pages={58–63}
}
Allelic loss of chromosome 1p predicts increased chemosensitivity and better survival in oligodendroglial tumors. Clinical testing for 1p loss in oligodendroglial tumors at our hospital has allowed us to postulate that certain histological appearances are associated with 1p allelic status. Forty-four cases received for genetic testing were diagnosed by referring pathologists as pure low-grade oligodendroglioma. Central neuropathological review divided the series equally into 22 cases with… 

Tables from this paper

Molecular–genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort
TLDR
It was revealed that although chromosome 7q/7 gain was more frequent in “astrocytic” gliomas, other CNAs occurred at a similar frequency in both groups, and Histopathological re-assessment by a single pathologist showed consistent results.
The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making.
TLDR
The results suggest that the association between long-term survival and 1p loss in oligodendroglioma is unrelated to treatment and the true value of the allelic loss of 1p and its implication for clinical decision making is better determined.
Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology.
  • C. Nutt
  • Medicine
    Neurosurgical focus
  • 2005
TLDR
The author will summarize advances, thus attempting to highlight the molecular genetic study of oligodendrogliomas as a model for improved clinical management in the field of neurooncology.
Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors
TLDR
Although the prediction of 1p status based solely on the morphologic features seems to be difficult, the immunohistochemistry for p53 is a useful tool in that p53 overexpression is closely related to the 1p‐intact status in oligodendroglial tumors.
Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro‐Oncology
TLDR
It is proposed that clinical decisions in the management of patients with oligodendroglial tumors should be based on the combined assessment of clinical and neuroimaging features, histological classification and grading, as well as molecular genetic characteristics.
Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors
TLDR
Comparative analysis of several features indicated that the 1p/19q LOH tumors were associated with two histological features, “tumor cellularity” and “perinuclear halo,’ and low O6-methylguanine-DNA-methyltransferase (MGMT) expression and high cytoplasmic glutathione S-transferase pi (GST-π) expression.
Phenotype versus genotype in gliomas displaying inter- or intratumoral histological heterogeneity.
TLDR
The gliomas in this study were more homogeneous in their genotype than their histological phenotype with regions of differing histological subtype indistinguishable by the genetic markers investigated, supporting a monoclonal origin of these tumors.
Pathology and Genetics of Gliomas.
TLDR
The updated WHO classification of CNS tumors (2016) considers not only phenotype, but also some genetic characteristics of gliomas, which may help clinicians to determine proper treatment strategy and to predict prognosis.
Correlation of Molecular Genetics with Molecular and Morphological Imaging in Gliomas with an Oligodendroglial Component
TLDR
Dissociation of uptake of contrast agents and radiotracers suggests independent deregulation of the blood–brain barrier breakdown and metabolism during disease progression of oligodendroglial neoplasms, and the association of elevated metabolism with 1p/19q loss, particularly in low-grade tumors, may have implications for clinical management.
Oligodendrogliomas: impact of molecular genetics on treatment.
TLDR
Clinical, pathological and molecular genetic findings on oligodendrogliomas and oligoastrocytomas of WHO Grades II and III are compiled to present a brief overview on recent developments.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
  • J. S. Smith, A. Perry, R. Jenkins
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
TLDR
Combined loss of 1p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade, and could potentially improve existing strategies for patient stratification and management.
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
TLDR
Allelic loss (or loss of heterozygosity) of chromosome 1p is a statistically significant predictor of chemosensitivity, and combined loss involving chromosomes 1p and 19q is statistically significantly associated with both chemos sensitivity and longer recurrence-free survival after chemotherapy.
Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.
Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.
  • Y. Ino, R. Betensky, D. Louis
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2001
TLDR
The possibility that therapeutic decisions at the time of diagnosis might be tailored to particular genetic subtypes of anaplastic oligodendroglioma is raised, for the first time, in this group of patients in whom therapeutic management was not uniform.
Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma
TLDR
Findings show that the astrocytic and oligodendroglial portions of oligoastrocytoma share molecular genetic features and probably are of monoclonal origin.
Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas
TLDR
The ominous sign of the presence of gemistocytes in oligodendrogliomas confirms some earlier reports about the prognostic significance of this cell type in astrocytomas.
Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype
TLDR
Using 115 human diffuse gliomas, regions of common allelic loss on chromosomes 1 and 19 were localized and the association of these deletion intervals with glioma histological subtypes was assessed, suggesting not only locations of putative tumor suppressor genes, but also a simple assay for assessment of 1p and 19q alterations as diagnostic and prognostic markers.
The Glial and Mesenchymal Elements of Gliosarcomas Share Similar Genetic Alterations
TLDR
The hypothesis that the sarcomatous component of a gliosarcoma either arises from the same common precursor cell as the gliomatous portion, or it arises fromThe gliom atous portion itself is supported.
Interphase cytogenetics of glioblastoma and gliosarcoma
TLDR
It is concluded that numerical chromosome aberrations can be detected in routinely processed brain tumor biopsy specimens using interphase cytogenetics, making retrospective studies feasible, and glioblastomas show intratumoral cytogenetic heterogeneity with formation of monoclonal cell clusters.
...
1
2
...